Mumps virus as a potential oncolytic agent
This document relates to methods and materials for virotherapy. For example, this document provides methods and materials for treating cancer using a recombinant mumps virus as an oncolytic agent.
1. A recombinant mumps virus (MuV) having oncolytic anti-cancer activity, wherein said recombinant MuV comprises nucleic acid encoding a modified RNA polymerase large (L) subunit protein comprising a N to H substitution at amino acid 1631 as numbered in SEQ ID NO:10.
2. The recombinant MuV of claim 1 , wherein said recombinant MuV is a replication competent MuV.
3. The recombinant MuV of claim 1 , wherein said modification in an RNA polymerase L subunit coding sequence comprises an A to C substitution at nucleotide 13328 as numbered in SEQ ID NO: 1.
4. A method for treating a patient having cancer, the method comprising:
administering to the patient a recombinant mumps virus (MuV) having oncolytic anticancer activity, wherein said recombinant MuV comprises nucleic acid encoding a modified RNA polymerase large (L) subunit protein comprising a N to H substitution at amino acid 1631 as numbered in SEQ ID NO:10.
5. The method of claim 4 , wherein the cancer is a blood cancer selected from leukemia, lymphoma, or myeloma.
6. The method claim 5 , wherein the blood cancer is myeloma.
7. The method of claim 4 , wherein the cancer is a carcinoma selected from prostate cancer, breast cancer, hepatocellular carcinoma, lung cancer, or colorectal carcinoma.
8. The method of claim 7 , wherein the carcinoma is colorectal carcinoma.
9. The method of claim 4 , wherein said recombinant MuV is a replication competent MuV.
10. The method of claim 4 , wherein said modification in an RNA polymerase L subunit coding sequence comprises an A to C substitution at nucleotide 13328 as numbered in SEQ ID NO:1.
11. The method of claim 4 , further comprising administering ruxolitinib.
12. An expression construct comprising a nucleotide sequence encoding a recombinant MuV having oncolytic anti-cancer activity, wherein said recombinant MuV comprises nucleic acid encoding a modified RNA polymerase large (L) subunit protein comprising a N to H substitution at amino acid 1631 as numbered in SEQ ID NO:10.
13. The expression construct of claim 12 , wherein said recombinant MuV is a replication competent MuV.
14. The expression construct of claim 12 , wherein said modification in an RNA polymerase L subunit coding sequence comprises an A to C substitution at nucleotide 13328 as numbered in SEQ ID NO: 1.
15. A method for treating a patient having cancer, the method comprising:
administering to the patient an expression construct comprising a nucleotide sequence encoding a recombinant mumps virus (MuV) having oncolytic anti-cancer activity, wherein said recombinant MuV comprises nucleic acid encoding a modified RNA polymerase large (L) subunit protein comprising a N to H substitution at amino acid 1631 as numbered in SEQ ID NO:10.
16. The method of claim 15 , wherein the cancer is a blood cancer selected from leukemia, lymphoma, or myeloma.
17. The method claim 16 , wherein the blood cancer myeloma.
18. The method of claim 15 , wherein the cancer is a carcinoma selected from prostate cancer, breast cancer, hepatocellular carcinoma, lung cancer, or colorectal carcinoma.
19. The method of claim 18 , wherein the carcinoma is colorectal carcinoma.
20. The method of claim 15 , wherein said recombinant MuV is a replication competent MuV.
21. The method of claim 15 , wherein said modification in an RNA polymerase L subunit coding sequence comprises an A to C substitution at nucleotide 13328 as numbered in SEQ ID NO: 1.
22. The method of claim 15 , further comprising administering ruxolitinib.